Literature DB >> 8291573

Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.

M C Kurth1, J H Kurth.   

Abstract

Aberrant detoxification of environmental agents may be the basis for an inherited predisposition to Parkinson's disease. A CYP2D6 genetic marker of the debrisoquine hydroxylase "poor metabolizer" phenotype was found to be significantly increased in Parkinson's disease patients compared to controls, as has been shown in previous studies. Presence of this marker gives an odds ratio of 1.86 for Parkinson's disease (95% confidence interval 1.33-2.39, P < 0.02). For comparison, a CYP1A1 polymorphism, which is not known to be associated with aberrant drug metabolism, showed no association with Parkinson's disease in our study.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8291573     DOI： 10.1002/ajmg.1320480311

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN： 0148-7299


  9 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

Review 2.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

Review 3.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

4.  The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease.

Authors:  T Gasser; B Müller-Myhsok; A Supala; E Zimmer; G Wieditz; Z K Wszolek; P Vieregge; V Bonifati; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

5.  Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?

Authors:  K Wilhelmsen; D Mirel; K Marder; M Bernstein; A Naini; S M Leal; L J Cote; M X Tang; G Freyer; J Graziano; R Mayeux
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

6.  Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.

Authors:  Kwi Hye Koh; Xian Pan; Hong-Wu Shen; Samuel L M Arnold; Ai-Ming Yu; Frank J Gonzalez; Nina Isoherranen; Hyunyoung Jeong
Journal:  J Biol Chem       Date:  2013-12-06       Impact factor: 5.157

7.  Arg296 to Cys296 polymorphism in exon 6 of cytochrome P-450-2D6 (CYP2D6) is not associated with multiple system atrophy.

Authors:  O Bandmann; G K Wenning; N P Quinn; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

8.  Acetaldehyde and parkinsonism: role of CYP450 2E1.

Authors:  Francesca Vaglini; Cristina Viaggi; Valentina Piro; Carla Pardini; Claudio Gerace; Marco Scarselli; Giovanni Umberto Corsini
Journal:  Front Behav Neurosci       Date:  2013-06-21       Impact factor: 3.558

9.  CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis.

Authors:  Yu Lu; Cuiju Mo; Zhiyu Zeng; Siyuan Chen; Yantong Xie; Qiliu Peng; Yu He; Yan Deng; Jian Wang; Li Xie; Jie Zeng; Shan Li; Xue Qin
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.